Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 18/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596307 | 0.86 | MAT2A (0.58) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596379 | 0.83 | MAT2A (0.47) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596202 | 0.79 | MAT2A (0.46) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596195 | 0.79 | MAT2A (0.50) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596206 | 0.74 | MAT2A (0.46) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22103504 | 0.73 | MAT2A (0.75) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596190 | 0.71 | MAT2A (0.42) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596312 | 0.69 | MAT2A (0.58) | MAT2A | |
| SCHEMBL24596273 | 0.69 | MAT2A (0.58) | MAT2A | |
| SCHEMBL24596241 | 0.69 | MAT2A (0.60) | MAT2AHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |